SEARCH

SEARCH BY CITATION

References

  • 1
    Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2004; 126: 234S64S.
  • 2
    Curtin R, Cox D, Fitzgerald D. Clopidogrel and ticlopidine. In: MichelsonAD, ed. Platelets. New York: Academic Press/Elsevier Science, 2002: 787801.
  • 3
    Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004; 110: e48993.
  • 4
    Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 290813.
  • 5
    Matetzky S, Shenkman B, Guetta V, Schechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 31715.
  • 6
    Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bater ER. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 16671.
  • 7
    Cattaneo M. Aspirin and clopidogrel: efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 19807.
  • 8
    Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL, Alessi MC. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4: 5429.
  • 9
    Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US. Clopidogrel effect on platelet reactivity in patients with stent thrombosis. Results of the CREST study. J Am Coll Cardiol 2005; 46: 182732.
  • 10
    Barnard MR, Krueger LA, Frelinger III AL, Furman MI, Michelson AD. Whole blood analysis of leukocyte-platelet aggregates. In: RobinsonJP, DarzynkiewiczZ, DeanPN, DresslerLG, RabinovitchPS, StewartCC, et al., eds. Current Protocols in Cytometry. New York: John Wiley & Sons, 2002: 6.10.16.10.17.
  • 11
    Michelson AD, Barnard MR, Krueger LA, Frelinger III AL, Furman MI. Flow cytometry. In: MichelsonAD, ed. Platelets. New York: Academic Press/Elsevier Science, 2002: 297315.
  • 12
    Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 15337.
  • 13
    Hato T, Ginsberg MH, Shattil SJ. Integrin alphaIIb-beta3. In: MichelsonAD, ed. Platelets. New York: Academic Press/Elsevier Science, 2002: 10516.
  • 14
    McEver RP. P-selectin/PSGL-1 and other interactions between platelets, leukocytes, and endothelium. In: MichelsonAD, ed. Platelets. New York: Academic Press/Elsevier Science, 2002: 13955.
  • 15
    Krueger LA, Barnard MR, Frelinger Jr AL, Furman MI, Michelson AD. Immunophenotypic analysis of platelets. In: RobinsonJP, DarzynkiewiczZ, DeanPN, DresslerLG, RabinovitchPS, StewartCC, et al., eds, Current Protocols in Cytometry. New York: John Wiley & Sons, 2002: 6.10.16.10.17.
  • 16
    Schwarz G. Estimating the dimension of a model. Ann Stat 1978; 6: 4614.
  • 17
    Serebruany VL, Gurbel PA, Shustov AR, Ohman EM, Topol EJ. Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction. Am Heart J 1998; 136: 398405.
  • 18
    Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 98995.
  • 19
    Hetherington SL, Singh RK, Lodwick D, Thompson JR, Goodall AH, Samani NJ. Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol 2005; 25: 2527.
  • 20
    Hechler B, Zhang Y, Eckly A, Cazenave JP, Gachet C, Ravid K. Lineage-specific overexpression of the P2Y1 receptor induces platelet hyper-reactivity in transgenic mice. J Thromb Haemost 2003; 1: 15563.
  • 21
    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Barrera-Ramirez C, Sabate M, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Boss TA, Macaya G. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005; 115: 1018.
  • 22
    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Banuelos C, Hernandez-Antolin R, Escaned J, Moreno R, Alfonso F, Macaya C. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004; 25: 190310.
  • 23
    Samara WM, Bliden KP, Tantry US, Gurbel PA. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res 2005; 115: 8994.
  • 24
    Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 8592.
  • 25
    Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 2004; 93: 4568.
  • 26
    Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets. Results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (CLEAR PLATELETS) study. Circulation 2005; 111: 11539.
  • 27
    Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 13926.
  • 28
    Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111: 2099106.
  • 29
    Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Buttner HJ, Neumann FJ. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005; 111: 25604.
  • 30
    Brandt JT, Payne CD, Weerakkody G, Behounek BD, Naganuma H, Jakubowski JA, Wiriott SD, Winters KJ. Superior responder rate for inhibition of platelet aggregation with a 60 mg loading dose of prasugrel (CD-747, LY640315) compared with a 300 mg loading dose of clopidogrel. J Am Coll Cardiol 2005; 45: 87A.
  • 31
    Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention. Results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111: 336673.